HemCon Medical Technologies
Tricol Biomedical is a fully integrated medical device company dedicated to saving lives through innovative hemostatic and wound-care solutions. With a focus on bleeding control and wound management, the company develops, manufactures, and markets proprietary products like HemCon, OneStop, and m.doc, which are used worldwide across various medical settings, military, and consumers. Their mission is to achieve zero preventable deaths due to blood loss, driven by innovation, scientific research, and global partnerships. The company emphasizes collaboration with scientific, compliance, and production teams to ensure reliable supply chains and product availability, even during global disruptions. Tricol’s advanced hemostatic devices, including Chito+™ and m.doc®, are manufactured in the USA and distributed globally, including in hospitals, outpatient settings, emergency clinics, and home first-aid kits. They have a strong focus on innovation, with over 60 patents, and actively participate in scientific research and publications to validate their solutions.
Industries
Nr. of Employees
medium (51-250)
HemCon Medical Technologies
720 SW Washington Street, Suite 200, Portland, Oregon 97205-3504 USA
Patents
Products
Freeze-dried mucoadhesive chitosan hemostatic bandage
Soft, porous, freeze-dried mucoadhesive chitosan bandage designed for rapid external hemorrhage control in trauma and procedural settings.
Chitosan-coated wound packing gauze
Flexible gauze dressings coated with chitosan for deep wound packing and contact with bleeding sources to assist hemorrhage control.
Small-area vascular/procedural hemostatic patch
Compact hemostatic patch intended for vascular access and percutaneous catheter or tube sites to control bleeding and provide a bacterial barrier.
Investigational absorbable biocompatible chitosan dressing
Modified absorbable chitosan dressing developed for internal application with preclinical demonstration of bioabsorption and biocompatibility for sustained internal bleeding control.
Freeze-dried mucoadhesive chitosan hemostatic bandage
Soft, porous, freeze-dried mucoadhesive chitosan bandage designed for rapid external hemorrhage control in trauma and procedural settings.
Chitosan-coated wound packing gauze
Flexible gauze dressings coated with chitosan for deep wound packing and contact with bleeding sources to assist hemorrhage control.
Small-area vascular/procedural hemostatic patch
Compact hemostatic patch intended for vascular access and percutaneous catheter or tube sites to control bleeding and provide a bacterial barrier.
Investigational absorbable biocompatible chitosan dressing
Modified absorbable chitosan dressing developed for internal application with preclinical demonstration of bioabsorption and biocompatibility for sustained internal bleeding control.
Services
Collaborative R&D and engineering to integrate chitosan-based hemostatic materials into partner medical devices and procedural workflows under contract.
Negotiation and management of distributor onboarding, group purchasing organization contracts, and regional commercial representation to place hemostatic products into clinical and consumer channels.
Management of sample requests, shipping logistics, onsite evaluation coordination, and collection of standardized evaluation feedback to support clinical assessment and procurement decisions.
Licensing of chitosan-based material technologies and collaboration on field-of-use or territory-limited licenses to enable third-party product development.
Collaborative R&D and engineering to integrate chitosan-based hemostatic materials into partner medical devices and procedural workflows under contract.
Negotiation and management of distributor onboarding, group purchasing organization contracts, and regional commercial representation to place hemostatic products into clinical and consumer channels.
Management of sample requests, shipping logistics, onsite evaluation coordination, and collection of standardized evaluation feedback to support clinical assessment and procurement decisions.
Licensing of chitosan-based material technologies and collaboration on field-of-use or territory-limited licenses to enable third-party product development.
Expertise Areas
- Hemostatic biomaterials development
- Bioabsorbable dressing design
- Preclinical and clinical study design and execution
- Medical device manufacturing and lyophilization
Key Technologies
- Mucoadhesive chitosan materials
- Chitosan derivatization and molecular characterization
- Bioabsorbable controlled-dissolution formulations
- Lyophilization (freeze-drying) for porous dressings
News & Updates
The Blood Stops Here®
Our vision is to achieve zero preventable deaths due to blood loss.
Science Behind Our Products
Tricol's proprietary chitosan, Chito+™, is used in hemostatic products to rapidly control bleeding and support natural coagulation.
Patent for Modified Chitosan Dressing in GI Tract
The US Patent and Trademark Office granted Tricol a new patent (#11,564,673) for its modified chitosan dressing designed for gastrointestinal bleeding control for up to 96 hours.
Expansion of Product Offerings and Strategic Partnerships
Tricol has expanded its product lines and entered into strategic distribution agreements globally, including with Medline, Salvin Dental, and others, to increase access to its hemostatic solutions.
Recognition and Innovation in Wound Care
Tricol was recognized as a Top 10 Wound Care Solutions Company in 2022 and continues to innovate with over 60 patents and numerous clinical publications.
Preclinical Study on Bioabsorbable Chitosan Dressings
A study demonstrated the bioabsorption and biocompatibility of Tricol's ABC chitosan dressing in animal models, showing promising internal bleeding control.
The Blood Stops Here®
Our vision is to achieve zero preventable deaths due to blood loss.
Science Behind Our Products
Tricol's proprietary chitosan, Chito+™, is used in hemostatic products to rapidly control bleeding and support natural coagulation.
Patent for Modified Chitosan Dressing in GI Tract
The US Patent and Trademark Office granted Tricol a new patent (#11,564,673) for its modified chitosan dressing designed for gastrointestinal bleeding control for up to 96 hours.
Expansion of Product Offerings and Strategic Partnerships
Tricol has expanded its product lines and entered into strategic distribution agreements globally, including with Medline, Salvin Dental, and others, to increase access to its hemostatic solutions.
Recognition and Innovation in Wound Care
Tricol was recognized as a Top 10 Wound Care Solutions Company in 2022 and continues to innovate with over 60 patents and numerous clinical publications.
Preclinical Study on Bioabsorbable Chitosan Dressings
A study demonstrated the bioabsorption and biocompatibility of Tricol's ABC chitosan dressing in animal models, showing promising internal bleeding control.